Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:

Surrogate Endpoints Envisioned For Heart Failure Diagnostic Trials

This article was originally published in The Gray Sheet

  • News

Executive Summary

Medical device firms attempting to validate surrogate endpoints in clinical trials may benefit from early-stage collaborations with pharmaceutical companies, according to CDRH Cardiovascular Devices Branch Chief Bram Zuckerman, MD

You may also be interested in...



Heart Failure Device Trial Investigators Search For Metrics Beyond Mortality

FDA should collaborate with the Heart Failure Society of America to draft guidelines for composite and surrogate endpoints in heart failure device trials, HFSA workshop participants urged April 1

Chinese Firms Up Their Game In Novel Flu Antiviral Development

Joincare Pharmaceutical and partner TaiGen Biotechnology tout preliminary Phase III results in uncomplicated acute influenza for TG-1000, a homegrown follower of Shionogi/Roche’s oral antiviral Xofluza. Novel antivirals for flu were hotly pursued by Chinese developers throughout 2023.

Table

View full table

Tags:
Latest Headlines

Ultrahuman Expands Wearable Medtech Production Into US After $35M Funding Round

Cochlear’s Osia System Receives Expanded FDA Clearance For Use In Younger Children

MAISI: Navigating The 'Valley Of Death' In Medtech Research Translation

Second EU MDR Notified Body Designated In France

See All
UsernamePublicRestriction

Register

MT020070

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By